ClinicalTrials.gg
CompletedNCT02963922SCALE™ InsulinUpdated Mar 30, 2020Results posted

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

A Phase 3 interventional study of Liraglutide 3.0 mg and Placebo in Metabolism and Nutrition Disorder and Obesity, sponsored by Novo Nordisk A/S. Completed at 54 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-30.

Primary conditionObesityRegistry: Nutrition DisordersReclassifiedWhy we changed it
Registry
Nutrition Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Nutrition Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.

Enrollment
7th of 79
396 · median 70
Started
2017
with 11 others
Phase 3
17 of 79
1 open now
Registered
34th of 79
by date
Lead sponsor
16 of 79
Novo Nordisk A/S

Among the 79 studies testing liraglutide in Obesity, this one is the 7th largest by enrollment, is one of 12 that started in 2017, is one of 17 in phase 3, and was the 34th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies testing liraglutide in Obesity, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.

03

Conditions studied

  • Metabolism and Nutrition Disorder
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 396 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nutrition Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial - Diagnosed with type 2 diabetes mellitus - Treatment with up to 2 OADs (oral anti-diabetic) (metformin, glitazone, SGLT-2 inhibitor (sodium-glucose cotransporter-2 inhibitors) or sulphonylurea) - Stable treatment with basal insulin according to its label (no requirement of minimum or maximum dose) for at least 90 days prior to screening, as judged by the investigator - (glycosylated ) 6.0-10.0% (both inclusive) - (body mass index) equal to or above 27 kg/m\^2 - Age at least 18 years at the time of signing informed consent Exclusion Criteria: - Diagnosis of type 1 diabetes - Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8 (see Section 8.2.3) - Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator - Unable or unwilling to perform self-monitoring of plasma glucose according to the protocol and to keep a diabetes diary - Treatment with any hypoglycaemic medications other than OADs and basal insulin within the past 90 days prior to screening - Treatment with a DPP-IV (dipeptidyl peptidase-4) inhibitor within the past 90 days prior to screening - Recent history of cardiovascular disease (myocardial infarction or stroke within the past 6 months), severe congestive heart failure ( class III, IV), or second degree or greater heart block - Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) - Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using an adequate method (adequate contraceptive measure as required by local regulation or practice) - For Germany: Only highly effective methods of birth control are accepted (i.e. one that results in less than 1% per year failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine device), or sexual abstinence or vasectomised partner - Use in past 90 days of medications known to induce significant weight loss (e.g., prescription weight loss medications) or weight gain (e.g., chronic use of oral , second generation antipsychotics) - History of pancreatitis (acute or chronic) - History of major depressive disorder within the past 2 years - Any lifetime history of a suicide attempt - Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic above or equal to 180 mmHg or diastolic above or equal to110 mmHg). - History of (except for non-melanoma skin cancer) within the past 5 years

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
396 participants (actual)

Study arms

  • Experimental
    liraglutide 3.0 mg

    Drug: Liraglutide 3.0 mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Injected subcutaneously (s.c., under the skin) once daily

  • DrugPlacebo

    Injected subcutaneously (s.c., under the skin) once daily

07

What researchers measure

Primary outcomes

  1. Change in Body Weight (%)

    Change in body weight from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \[AEs\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).

    Time frame: Week 0, week 56

  2. Participants Losing at Least 5% of Baseline Body Weight

    The estimated percentage of participants losing at least 5% of baseline (week 0) body weight at week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \[AEs\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).

    Time frame: Week 56

Secondary outcomes

  1. Participants Losing More Than 10% of Baseline Body Weight at Week 56

    The estimated percentage of participants losing more than 10% of baseline (week 0) body weight at week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \[AEs\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).

    Time frame: Week 56

  2. Change in Waist Circumference

    Change in waist circumference from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).

    Time frame: Week 0, week 56

  3. Change in HbA1c

    Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).

    Time frame: Week 0, week 56

  4. Change in FPG

    Change in fasting plasma glucose (FPG) from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).

    Time frame: Week 0, week 56

  5. Change in Short Form-36 (SF-36) v2.0 Acute, Physical Functioning Score

    SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline (week 0) in SF-36 physical functioning score was presented based on in-trial data and on-drug data. A positive change score indicates an improvement since baseline.

    Time frame: Week 0, week 56

  6. Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT), Physical Function Domain (5-items) Score

    Change in IWQoL-Lite for CT physical function domain (5-items) score. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. The endpoint was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).

    Time frame: Week 0, week 56

  7. Change in Total Daily Insulin Dose (U)

    Change in total daily insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  8. Change in Total Daily Basal Insulin Dose (% of Pre-trial Dose in U)

    Change in total daily basal insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  9. Change in Total Daily Basal Insulin Dose (U/kg)

    Change in total daily basal insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  10. Change in Total Daily Insulin Dose (U/kg)

    Change in total daily insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  11. Change in 7-point SMPG Profile Mean Daytime Glucose Value

    Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner and at bedtime. Change from baseline (week 0) to week 56 in 7-point self-measured plasma glucose (SMPG) profile mean daytime glucose value was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  12. Change in sBP and dBP

    Change in systolic blood pressure (sBP) and diastolic blood pressure (dBP) from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  13. Change in Lipids -Total Cholesterol, HDL, LDL, VLDL, Triglycerides and FFA

    Change in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, triglycerides and free fatty acids (FFA) from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  14. Change in SF-36: Sub-domains

    SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in the sub-domain scores was presented based on in-trial data. A positive change score indicates an improvement since baseline. Results are presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  15. Change in SF-36: Physical Component Summary (PCS)

    Change in short form 36 v2.0 acute domain physical component summary (PCS) from baseline (week 0) to week 56 was presented based on in-trial data. SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. It consists of 2 component summary measures that further summarize 8 health domain scales. The physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.

    Time frame: Week 0, week 56

  16. Change in SF-36: Mental Component Summary (MCS)

    Change in short form 36 v2.0 acute domain mental component summary (MCS) from baseline (week 0) to week 56 was presented based on in-trial data. SF- 36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.

    Time frame: Week 0, week 56

  17. Change in IWQoL-Lite for CT: Pain/Discomfort Domain Score

    Change in IWQoL-Lite for CT pain and discomfort domain from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  18. Change in IWQoL-Lite for CT: Psychosocial Domain Score

    Change in IWQoL-Lite for CT psychosocial domain from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  19. Change in IWQoL-Lite for CT: Total Score

    Change in IWQoL-Lite for CT total score from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  20. Weight Related Sign and Symptom (WRSS) Measure, Categorical Responses

    The WRSS measure is a questionnaire under development. The version applied in this study has 10 items that measure the presence and bothersomeness of 10 weight-related symptoms. Each item has a categorical part with answers on the following 5 possible levels: 'Never/Almost never', 'Rarely', 'Sometimes', 'Often' and 'Almost always/Always'. Number of participants in each category at baseline (week 0) and week 56 was presented. Scoring algorithm was not available prior to database lock and therefore it was decided and documented in the statistical analysis plan that WRSS total score was not to be calculated and analyzed.

    Time frame: Week 0, week 56

  21. Participants Who Achieved (Yes/no): HbA1c <7% and Weight Loss ≥5%

    Percentage of participants who achieved HbA1c \<7% and weight loss ≥5% from baseline at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 56

  22. Participants Who Achieved (Yes/no): HbA1c <7%, Weight Loss ≥5% and no Documented Symptomatic Hypoglycaemia

    Percentage of participants who achieved HbA1c \<7%, weight loss ≥5% from baseline and no documented symptomatic hypoglycaemia at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 56

  23. Participants Who Achieved (Yes/no): ≥4.3 T-score Points Increase From Baseline in SF-36 Acute Physical Functioning Score

    Percentage of participants who achieved ≥4.3 T-score points increase from baseline in SF-36 acute physical functioning score at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 56

  24. Participants Who Achieved (Yes/no): ≥3.8 T-score Points Increase From Baseline in SF-36 Acute PCS

    Percentage of participants who achieved ≥3.8 T-score points increase from baseline in SF-36 acute PCS at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 56

  25. Participants Who Achieved (Yes/no): ≥4.6 T-score Points Increase From Baseline in SF-36 Acute MCS

    Percentage of participants who achieved ≥4.6 T-score points increase from baseline in SF-36 acute MCS at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 56

  26. Responder Definition Value for IWQoL-Lite for CT Physical Function Domain Score

    Percentage of participants who achieve responder definition value for IWQoL-Lite for CT physical function domain score was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 56

  27. Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant administered a medicinal product, and which does not necessarily have a causal relationship with this treatment. Number of AEs from randomisation to until the end of the post-treatment follow-up period (30 days). Results based on in-trial data was presented. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0 to week 56 + 30 days

  28. Number of Hypoglycaemic Episodes

    Number of hypoglycaemic episodes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0 to week 56 + 30 days

  29. Change in Physical Examination

    Physical examination parameters are categorised as abdomen; gastrointestinal system; cardiovascular system; central and peripheral nervous system; general appearance; head, eyes, ears, nose, throat (ENT) and neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at baseline (week -1) and week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week -1, week 56

  30. Change in Resting Pulse

    Change from baseline (week -1) to week 56 in resting pulse was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week -1, week 56

  31. Change in Electrocardiogram (ECG)

    The ECGs were interpreted by the investigator at baseline (week -1) and week 56 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 56 were presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week -1, week 56

  32. Change in Laboratory Measurements (Haematology) - Haemoglobin

    Change from baseline (week 0) to week 56 in haemoglobin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  33. Change in Laboratory Measurements (Haematology) - Haematocrit

    Change from baseline (week 0) to week 56 in Haematocrit was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  34. Change in Laboratory Measurements (Haematology) - Erythrocytes

    Change from baseline (week 0) to week 56 in erythrocytes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  35. Change in Laboratory Measurements (Haematology) - Thrombocytes, Leukocytes

    Change from baseline (week 0) to week 56 in thrombocytes and leukocytes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  36. Change in Laboratory Parameters (Biochemistry) - Albumin

    Change from baseline (week 0) to week 56 in albumin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  37. Change in Laboratory Parameters (Biochemistry) - Alkaline Phosphatase, Alanine Aminotransferase, Amylase, Aspartate Aminotransferase and Lipase

    Change from baseline (week 0) to week 56 in alkaline phosphatase, alanine aminotransferase, amylase, aspartate aminotransferase and lipase was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  38. Change in Laboratory Parameters (Biochemistry) - Bicarbonate, Total Calcium, Potassium, Sodium and Urea

    Change from baseline (week 0) to week 56 in bicarbonate, total calcium, potassium, sodium and urea was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  39. Change in Laboratory Parameters (Biochemistry) - Total Bilirubin and Creatinine

    Change from baseline (week 0) to week 56 in total bilirubin and creatinine was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  40. Change in Laboratory Parameters (Biochemistry) - High Sensitive C-reactive Protein

    Change from baseline (week 0) to week 56 in high sensitive C-reactive protein was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  41. Change in Laboratory Parameters (Biochemistry) - eGFR

    Change from baseline (week 0) to week 56 in estimated GFR serum using Modification of Diet in Renal Disease (MDRD) formula was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  42. Change in Laboratory Parameters (Biochemistry) - Uric Acid

    Change from baseline (week 0) to week 56 in uric acid was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  43. Change in Laboratory Parameters (Biochemistry) - Calcitonin

    Change from baseline (week 0) to week 56 in calcitonin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

  44. Change in Laboratory Parameters (Biochemistry) - Thyroid Stimulating Hormone

    Change from baseline (week 0) to week 56 in thyroid stimulating hormone was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

    Time frame: Week 0, week 56

08

Results

Posted Nov 27, 2019

Participant flow

The trial was conducted at 53 sites in Canada (7), Germany (7), Israel (6), Italy (4), Mexico (2), Turkey (7) and United States (20).

Participant flow — Overall Study
MilestoneLiraglutide 3.0 mgPlacebo
Started198198
Completed166168
Not completed3230
Withdrew: Adverse event156
Withdrew: Protocol deviation66
Withdrew: Lack of efficacy11
Withdrew: Lost to follow-up23
Withdrew: Other814

Outcome measures

PrimaryChange in Body Weight (%)

Change in body weight from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \[AEs\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).

Time frame:
Week 0, week 56
Reported as:
Mean · Percentage change
Change in Body Weight (%)
Percentage changeLiraglutide 3.0 mgPlacebo
In-trial observation period-6.0 ± 6.0-1.5 ± 5.4
On-drug observation period-6.5 ± 5.8-1.7 ± 5.2
Statistical analysis
  • Liraglutide 3.0 mg vs Placebo · ANCOVA · p = < .0001 · Treatment difference: -4.32 · 95% CI -5.48 to -3.16Liraglutide 3.0 mg - placebo
  • Liraglutide 3.0 mg vs Placebo · MMRM · p = < .0001 · Treatment difference: -5.10 · 95% CI -6.30 to -3.91Liraglutide 3.0 mg - placebo
PrimaryParticipants Losing at Least 5% of Baseline Body Weight

The estimated percentage of participants losing at least 5% of baseline (week 0) body weight at week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \[AEs\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).

Time frame:
Week 56
Reported as:
Number · Percentage of participants
Participants Losing at Least 5% of Baseline Body Weight
Percentage of participantsLiraglutide 3.0 mgPlacebo
In-trial observation period51.8023.98
On-drug observation period56.9221.83
Statistical analysis
  • Liraglutide 3.0 mg vs Placebo · Regression, Logistic · p = <.0001 · Odds ratio (or): 3.41 · 95% CI 2.19 to 5.31Liraglutide 3.0 mg/Placebo
  • Liraglutide 3.0 mg vs Placebo · Mixed model for repeated measurements · p = <.0001 · Odds ratio (or): 4.73 · 95% CI 3.04 to 7.36Liraglutide 3.0 mg/Placebo
SecondaryParticipants Losing More Than 10% of Baseline Body Weight at Week 56

The estimated percentage of participants losing more than 10% of baseline (week 0) body weight at week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \[AEs\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).

Time frame:
Week 56
Reported as:
Number · Percentage of participants
Participants Losing More Than 10% of Baseline Body Weight at Week 56
Percentage of participantsLiraglutide 3.0 mgPlacebo
In-trial observation period22.776.55
On-drug observation period22.565.58
SecondaryChange in Waist Circumference

Change in waist circumference from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).

Time frame:
Week 0, week 56
Reported as:
Mean · Centimeters (cm)
Change in Waist Circumference
Centimeters (cm)Liraglutide 3.0 mgPlacebo
In-trial observation period-5.40 ± 6.06-2.60 ± 5.72
On-drug observation period-5.71 ± 6.05-2.78 ± 5.63
SecondaryChange in HbA1c

Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).

Time frame:
Week 0, week 56
Reported as:
Mean · Percentage of HbA1c
Change in HbA1c
Percentage of HbA1cLiraglutide 3.0 mgPlacebo
In-trial observation period-1.1 ± 1.2-0.5 ± 1.2
On-drug observation period-1.2 ± 1.1-0.7 ± 1.0
SecondaryChange in FPG

Change in fasting plasma glucose (FPG) from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).

Time frame:
Week 0, week 56
Reported as:
Mean · Millimoles per liter (mmol/L)
Change in FPG
Millimoles per liter (mmol/L)Liraglutide 3.0 mgPlacebo
In-trial observation period-0.91 ± 3.13-0.68 ± 3.04
On-drug observation period-1.05 ± 3.08-0.96 ± 2.68
SecondaryChange in Short Form-36 (SF-36) v2.0 Acute, Physical Functioning Score

SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline (week 0) in SF-36 physical functioning score was presented based on in-trial data and on-drug data. A positive change score indicates an improvement since baseline.

Time frame:
Week 0, week 56
Reported as:
Mean · Score on a scale
Change in Short Form-36 (SF-36) v2.0 Acute, Physical Functioning Score
Score on a scaleLiraglutide 3.0 mgPlacebo
In-trial observation period2.5 ± 7.92.6 ± 7.3
On-drug observation period2.9 ± 7.82.5 ± 7.1
SecondaryChange in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT), Physical Function Domain (5-items) Score

Change in IWQoL-Lite for CT physical function domain (5-items) score. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. The endpoint was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).

Time frame:
Week 0, week 56
Reported as:
Mean · Score on a scale
Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT), Physical Function Domain (5-items) Score
Score on a scaleLiraglutide 3.0 mgPlacebo
In-trial observation period7.3 ± 22.56.8 ± 21.5
On-drug observation period8.2 ± 20.96.5 ± 21.8
SecondaryChange in Total Daily Insulin Dose (U)

Change in total daily insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Units of insulin dose (U)
Change in Total Daily Insulin Dose (U)
Units of insulin dose (U)Liraglutide 3.0 mgPlacebo
Change in Total Daily Insulin Dose (U)3 ± 3018 ± 38
SecondaryChange in Total Daily Basal Insulin Dose (% of Pre-trial Dose in U)

Change in total daily basal insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Percentage change
Change in Total Daily Basal Insulin Dose (% of Pre-trial Dose in U)
Percentage changeLiraglutide 3.0 mgPlacebo
Change in Total Daily Basal Insulin Dose (% of Pre-trial Dose in U)19 ± 12164 ± 139
SecondaryChange in Total Daily Basal Insulin Dose (U/kg)

Change in total daily basal insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Units of insulin dose per kilogram(U/kg)
Change in Total Daily Basal Insulin Dose (U/kg)
Units of insulin dose per kilogram(U/kg)Liraglutide 3.0 mgPlacebo
Change in Total Daily Basal Insulin Dose (U/kg)0.05 ± 0.330.15 ± 0.30
SecondaryChange in Total Daily Insulin Dose (U/kg)

Change in total daily insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · U/kg
Change in Total Daily Insulin Dose (U/kg)
U/kgLiraglutide 3.0 mgPlacebo
Change in Total Daily Insulin Dose (U/kg)0.05 ± 0.330.18 ± 0.37
SecondaryChange in 7-point SMPG Profile Mean Daytime Glucose Value

Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner and at bedtime. Change from baseline (week 0) to week 56 in 7-point self-measured plasma glucose (SMPG) profile mean daytime glucose value was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · mmol/L
Change in 7-point SMPG Profile Mean Daytime Glucose Value
mmol/LLiraglutide 3.0 mgPlacebo
Change in 7-point SMPG Profile Mean Daytime Glucose Value-2.2 ± 2.6-1.6 ± 2.8
SecondaryChange in sBP and dBP

Change in systolic blood pressure (sBP) and diastolic blood pressure (dBP) from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Millimeters of mercury (mmHg)
Change in sBP and dBP
Millimeters of mercury (mmHg)Liraglutide 3.0 mgPlacebo
sBP-6 ± 14-2 ± 15
dBP-3 ± 9-1 ± 9
SecondaryChange in Lipids -Total Cholesterol, HDL, LDL, VLDL, Triglycerides and FFA

Change in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, triglycerides and free fatty acids (FFA) from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · mmol/L
Change in Lipids -Total Cholesterol, HDL, LDL, VLDL, Triglycerides and FFA
mmol/LLiraglutide 3.0 mgPlacebo
Total cholesterol-0.12 ± 0.820.04 ± 0.69
HDL cholesterol0.05 ± 0.170.03 ± 0.17
LDL cholesterol-0.08 ± 0.720.05 ± 0.57
VLDL cholesterol-0.09 ± 0.35-0.04 ± 0.33
Triglycerides-0.21 ± 0.89-0.08 ± 0.80
Free fatty acids-0.10 ± 0.27-0.06 ± 0.34
SecondaryChange in SF-36: Sub-domains

SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in the sub-domain scores was presented based on in-trial data. A positive change score indicates an improvement since baseline. Results are presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Score on a scale
Change in SF-36: Sub-domains
Score on a scaleLiraglutide 3.0 mgPlacebo
Bodily Pain1.2 ± 8.31.2 ± 9.1
General Health1.9 ± 7.80.3 ± 7.7
Physical Functioning2.5 ± 7.92.6 ± 7.3
Role-physical0.8 ± 7.70.9 ± 8.0
Role Lim Emotion Prob-1.2 ± 8.1-0.3 ± 8.2
Mental Health-1.1 ± 8.6-1.1 ± 7.5
Social Functioning-0.7 ± 7.7-0.6 ± 6.3
Vitality1.0 ± 8.0-0.0 ± 7.7
SecondaryChange in SF-36: Physical Component Summary (PCS)

Change in short form 36 v2.0 acute domain physical component summary (PCS) from baseline (week 0) to week 56 was presented based on in-trial data. SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. It consists of 2 component summary measures that further summarize 8 health domain scales. The physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.

Time frame:
Week 0, week 56
Reported as:
Mean · Score on a scale
Change in SF-36: Physical Component Summary (PCS)
Score on a scaleLiraglutide 3.0 mgPlacebo
Change in SF-36: Physical Component Summary (PCS)2.7 ± 7.52.2 ± 7.2
SecondaryChange in SF-36: Mental Component Summary (MCS)

Change in short form 36 v2.0 acute domain mental component summary (MCS) from baseline (week 0) to week 56 was presented based on in-trial data. SF- 36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.

Time frame:
Week 0, week 56
Reported as:
Mean · Score on a scale
Change in SF-36: Mental Component Summary (MCS)
Score on a scaleLiraglutide 3.0 mgPlacebo
Change in SF-36: Mental Component Summary (MCS)-1.9 ± 7.9-1.7 ± 6.8
SecondaryChange in IWQoL-Lite for CT: Pain/Discomfort Domain Score

Change in IWQoL-Lite for CT pain and discomfort domain from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Score on a scale
Change in IWQoL-Lite for CT: Pain/Discomfort Domain Score
Score on a scaleLiraglutide 3.0 mgPlacebo
Change in IWQoL-Lite for CT: Pain/Discomfort Domain Score4.0 ± 22.14.6 ± 23.1
SecondaryChange in IWQoL-Lite for CT: Psychosocial Domain Score

Change in IWQoL-Lite for CT psychosocial domain from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Score on a scale
Change in IWQoL-Lite for CT: Psychosocial Domain Score
Score on a scaleLiraglutide 3.0 mgPlacebo
Change in IWQoL-Lite for CT: Psychosocial Domain Score5.4 ± 18.44.0 ± 16.7
SecondaryChange in IWQoL-Lite for CT: Total Score

Change in IWQoL-Lite for CT total score from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Score on a scale
Change in IWQoL-Lite for CT: Total Score
Score on a scaleLiraglutide 3.0 mgPlacebo
Change in IWQoL-Lite for CT: Total Score5.7 ± 17.64.8 ± 16.6
SecondaryWeight Related Sign and Symptom (WRSS) Measure, Categorical Responses

The WRSS measure is a questionnaire under development. The version applied in this study has 10 items that measure the presence and bothersomeness of 10 weight-related symptoms. Each item has a categorical part with answers on the following 5 possible levels: 'Never/Almost never', 'Rarely', 'Sometimes', 'Often' and 'Almost always/Always'. Number of participants in each category at baseline (week 0) and week 56 was presented. Scoring algorithm was not available prior to database lock and therefore it was decided and documented in the statistical analysis plan that WRSS total score was not to be calculated and analyzed.

Time frame:
Week 0, week 56
Reported as:
Count of participants · Participants
Weight Related Sign and Symptom (WRSS) Measure, Categorical Responses
ParticipantsLiraglutide 3.0 mgPlacebo
Week 0: Joint pain — Almost always/Always115
Week 0: Joint pain — Never/Almost never7485
Week 0: Joint pain — Often1718
Week 0: Joint pain — Rarely4742
Week 0: Joint pain — Sometimes4946
Week 56: Joint pain — Almost always/Always65
Week 56: Joint pain — Never/Almost never9575
Week 56: Joint pain — Often1217
Week 56: Joint pain — Rarely3539
Week 56: Joint pain — Sometimes3952
Week 0: Shortness of breath — Almost always/Always00
Week 0: Shortness of breath — Never/Almost never131140
Week 0: Shortness of breath — Often33
Week 0: Shortness of breath — Rarely4532
Week 0: Shortness of breath — Sometimes1921
Week 56: Shortness of breath — Almost always/Always11
Week 56: Shortness of breath — Never/Almost never137111
Week 56: Shortness of breath — Often53
Week 56: Shortness of breath — Rarely2846
Week 56: Shortness of breath — Sometimes1627
Week 0: Heat sensitivity — Almost always/Always89
Week 0: Heat sensitivity — Never/Almost never106109
Week 0: Heat sensitivity — Often1316
Week 0: Heat sensitivity — Rarely3431
Week 0: Heat sensitivity — Sometimes3731
Week 56: Heat sensitivity — Almost always/Always28
Week 56: Heat sensitivity — Never/Almost never9287
Week 56: Heat sensitivity — Often1213
Week 56: Heat sensitivity — Rarely4247
Week 56: Heat sensitivity — Sometimes3933
Week 0: Sexual desire — Almost always/Always88
Week 0: Sexual desire — Never/Almost never119121
Week 0: Sexual desire — Often1313
Week 0: Sexual desire — Rarely3532
Week 0: Sexual desire — Sometimes2322
Week 56: Sexual desire — Almost always/Always611
Week 56: Sexual desire — Never/Almost never105109
Week 56: Sexual desire — Often1811
Week 56: Sexual desire — Rarely3432
Week 56: Sexual desire — Sometimes2425
Week 0: Heavy sweating — Almost always/Always25
Week 0: Heavy sweating — Never/Almost never101104
Week 0: Heavy sweating — Often1514
Week 0: Heavy sweating — Rarely4038
Week 0: Heavy sweating — Sometimes4035
Week 56: Heavy sweating — Almost always/Always15
Week 56: Heavy sweating — Never/Almost never9892
Week 56: Heavy sweating — Often716
Week 56: Heavy sweating — Rarely5148
Week 56: Heavy sweating — Sometimes3027
Week 0: Low physical stamina — Almost always/Always28
Week 0: Low physical stamina — Never/Almost never7378
Week 0: Low physical stamina — Often2214
Week 0: Low physical stamina — Rarely5647
Week 0: Low physical stamina — Sometimes4549
Week 56: Low physical stamina — Almost always/Always34
Week 56: Low physical stamina — Never/Almost never7765
Week 56: Low physical stamina — Often1519
Week 56: Low physical stamina — Rarely5756
Week 56: Low physical stamina — Sometimes3544
Week 0: Foot pain — Almost always/Always57
Week 0: Foot pain — Never/Almost never114108
Week 0: Foot pain — Often1712
Week 0: Foot pain — Rarely3431
Week 0: Foot pain — Sometimes2838
Week 56: Foot pain — Almost always/Always27
Week 56: Foot pain — Never/Almost never10688
Week 56: Foot pain — Often1514
Week 56: Foot pain — Rarely2939
Week 56: Foot pain — Sometimes3540
Week 0: Trouble sleeping — Almost always/Always64
Week 0: Trouble sleeping — Never/Almost never119111
Week 0: Trouble sleeping — Often1110
Week 0: Trouble sleeping — Rarely3042
Week 0: Trouble sleeping — Sometimes3229
Week 56: Trouble sleeping — Almost always/Always63
Week 56: Trouble sleeping — Never/Almost never10498
Week 56: Trouble sleeping — Often1514
Week 56: Trouble sleeping — Rarely3833
Week 56: Trouble sleeping — Sometimes2440
Week 0: Back pain — Almost always/Always86
Week 0: Back pain — Never/Almost never9698
Week 0: Back pain — Often138
Week 0: Back pain — Rarely4940
Week 0: Back pain — Sometimes3244
Week 56: Back pain — Almost always/Always54
Week 56: Back pain — Never/Almost never9386
Week 56: Back pain — Often1311
Week 56: Back pain — Rarely4745
Week 56: Back pain — Sometimes2942
Week 0: Low energy — Almost always/Always02
Week 0: Low energy — Never/Almost never10290
Week 0: Low energy — Often1912
Week 0: Low energy — Rarely4642
Week 0: Low energy — Sometimes3150
Week 56: Low energy — Almost always/Always04
Week 56: Low energy — Never/Almost never8277
Week 56: Low energy — Often1616
Week 56: Low energy — Rarely4950
Week 56: Low energy — Sometimes4041
SecondaryParticipants Who Achieved (Yes/no): HbA1c <7% and Weight Loss ≥5%

Percentage of participants who achieved HbA1c \<7% and weight loss ≥5% from baseline at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 56
Reported as:
Number · Percentage of participants
Participants Who Achieved (Yes/no): HbA1c <7% and Weight Loss ≥5%
Percentage of participantsLiraglutide 3.0 mgPlacebo
Participants Who Achieved (Yes/no): HbA1c <7% and Weight Loss ≥5%39.913.6
SecondaryParticipants Who Achieved (Yes/no): HbA1c <7%, Weight Loss ≥5% and no Documented Symptomatic Hypoglycaemia

Percentage of participants who achieved HbA1c \<7%, weight loss ≥5% from baseline and no documented symptomatic hypoglycaemia at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 56
Reported as:
Number · Percentage of participants
Participants Who Achieved (Yes/no): HbA1c <7%, Weight Loss ≥5% and no Documented Symptomatic Hypoglycaemia
Percentage of participantsLiraglutide 3.0 mgPlacebo
Participants Who Achieved (Yes/no): HbA1c <7%, Weight Loss ≥5% and no Documented Symptomatic Hypoglycaemia10.13.5
SecondaryParticipants Who Achieved (Yes/no): ≥4.3 T-score Points Increase From Baseline in SF-36 Acute Physical Functioning Score

Percentage of participants who achieved ≥4.3 T-score points increase from baseline in SF-36 acute physical functioning score at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 56
Reported as:
Number · Percentage of participants
Participants Who Achieved (Yes/no): ≥4.3 T-score Points Increase From Baseline in SF-36 Acute Physical Functioning Score
Percentage of participantsLiraglutide 3.0 mgPlacebo
Participants Who Achieved (Yes/no): ≥4.3 T-score Points Increase From Baseline in SF-36 Acute Physical Functioning Score28.826.3
SecondaryParticipants Who Achieved (Yes/no): ≥3.8 T-score Points Increase From Baseline in SF-36 Acute PCS

Percentage of participants who achieved ≥3.8 T-score points increase from baseline in SF-36 acute PCS at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 56
Reported as:
Number · Percentage of participants
Participants Who Achieved (Yes/no): ≥3.8 T-score Points Increase From Baseline in SF-36 Acute PCS
Percentage of participantsLiraglutide 3.0 mgPlacebo
Participants Who Achieved (Yes/no): ≥3.8 T-score Points Increase From Baseline in SF-36 Acute PCS37.931.3
SecondaryParticipants Who Achieved (Yes/no): ≥4.6 T-score Points Increase From Baseline in SF-36 Acute MCS

Percentage of participants who achieved ≥4.6 T-score points increase from baseline in SF-36 acute MCS at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 56
Reported as:
Number · Percentage of participants
Participants Who Achieved (Yes/no): ≥4.6 T-score Points Increase From Baseline in SF-36 Acute MCS
Percentage of participantsLiraglutide 3.0 mgPlacebo
Participants Who Achieved (Yes/no): ≥4.6 T-score Points Increase From Baseline in SF-36 Acute MCS14.611.6
SecondaryResponder Definition Value for IWQoL-Lite for CT Physical Function Domain Score

Percentage of participants who achieve responder definition value for IWQoL-Lite for CT physical function domain score was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 56
Reported as:
Number · Percentage of participants
Responder Definition Value for IWQoL-Lite for CT Physical Function Domain Score
Percentage of participantsLiraglutide 3.0 mgPlacebo
Responder Definition Value for IWQoL-Lite for CT Physical Function Domain Score25.324.2
SecondaryAdverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant administered a medicinal product, and which does not necessarily have a causal relationship with this treatment. Number of AEs from randomisation to until the end of the post-treatment follow-up period (30 days). Results based on in-trial data was presented. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0 to week 56 + 30 days
Reported as:
Number · Adverse events
Adverse Events (AEs)
Adverse eventsLiraglutide 3.0 mgPlacebo
Adverse Events (AEs)12231148
SecondaryNumber of Hypoglycaemic Episodes

Number of hypoglycaemic episodes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0 to week 56 + 30 days
Reported as:
Number · Hypoglycaemic episodes
Number of Hypoglycaemic Episodes
Hypoglycaemic episodesLiraglutide 3.0 mgPlacebo
Number of Hypoglycaemic Episodes15381973
SecondaryChange in Physical Examination

Physical examination parameters are categorised as abdomen; gastrointestinal system; cardiovascular system; central and peripheral nervous system; general appearance; head, eyes, ears, nose, throat (ENT) and neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at baseline (week -1) and week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week -1, week 56
Reported as:
Count of participants · Participants
Change in Physical Examination
ParticipantsLiraglutide 3.0 mgPlacebo
Abdomen (week -1) Normal165169
Abdomen (week -1) Abnormal, NCS2525
Abdomen (week -1) Abnormal CS53
Abdomen (week 56) Normal167160
Abdomen (week 56) Abnormal, NCS1524
Abdomen (week 56) Abnormal, CS33
Gastrointestinal System (week -1) Normal185187
Gastrointestinal System (week -1) Abnormal NCS1010
Gastrointestinal System (week -1) Abnormal CS00
Gastrointestinal System (week 56) Normal175177
Gastrointestinal System (week 56) Abnormal NCS108
Gastrointestinal System (week 56) Abnormal CS00
Cardiovascular System (week-1) Normal183182
Cardiovascular System (week-1) Abnormal NCS1015
Cardiovascular System (week-1) Abnormal CS20
Cardiovascular System (week 56) Normal178175
Cardiovascular System (week 56) Abnormal NCS612
Cardiovascular System (week 56) Abnormal CS10
Nervous System (week -1) Normal158159
Nervous System (week -1) Abnormal NCS2625
Nervous System (week -1) Abnormal CS1113
Nervous System (week 56) Normal150149
Nervous System (week 56) Abnormal NCS2224
Nervous System (week 56) Abnormal CS1314
General Appearance (week -1) Normal150150
General Appearance (week -1) Abnormal NCS3936
General Appearance (week -1) Abnormal CS611
General Appearance (week 56) Normal156151
General Appearance (week 56) Abnormal NCS2327
General Appearance (week 56) Abnormal CS69
Head, eyes, ENTand Neck (week -1) Normal176182
Head, eyes, ENTand Neck (week -1) Abnormal NCS1713
Head, eyes, ENTand Neck (week -1) Abnormal CS22
Head, eyes, ENTand Neck (week 56) Normal168173
Head, eyes, ENTand Neck (week 56) Abnormal NCS1512
Head, eyes, ENTand Neck (week 56) Abnormal CS22
Lymph Node Palpation (week -1) Normal195197
Lymph Node Palpation (week -1) Abnormal NCS00
Lymph Node Palpation (week -1) Abnormal CS00
Lymph Node Palpation (week 56) Normal185186
Lymph Node Palpation (week 56) Abnormal NCS00
Lymph Node Palpation (week 56) Abnormal CS00
Musculoskeletal System (week -1) Normal180180
Musculoskeletal System (week -1) Abnormal NCS1316
Musculoskeletal System (week -1) Abnormal CS21
Musculoskeletal System (week 56) Normal171171
Musculoskeletal System (week 56) Abnormal NCS1314
Musculoskeletal System (week 56) Abnormal CS12
Respiratory System (week -1) Normal192192
Respiratory System (week -1) Abnormal NCS33
Respiratory System (week -1) Abnormal CS02
Respiratory System (week 56) Normal183185
Respiratory System (week 56) Abnormal NCS20
Respiratory System (week 56) Abnormal CS02
Skin (week -1) Normal155156
Skin (week -1) Abnormal NCS3633
Skin (week -1) Abnormal CS48
Skin (week 56) Normal150149
Skin (week 56) Abnormal NCS2829
Skin (week 56) Abnormal CS79
Thyroid Gland (week -1) Normal183187
Thyroid Gland (week -1) Abnormal NCS107
Thyroid Gland (week -1) Abnormal CS23
Thyroid Gland (week 56) Normal180178
Thyroid Gland (week 56) Abnormal NCS56
Thyroid Gland (week 56) Abnormal CS03
SecondaryChange in Resting Pulse

Change from baseline (week -1) to week 56 in resting pulse was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week -1, week 56
Reported as:
Mean · Beats/minute
Change in Resting Pulse
Beats/minuteLiraglutide 3.0 mgPlacebo
Change in Resting Pulse2 ± 9-0 ± 9
SecondaryChange in Electrocardiogram (ECG)

The ECGs were interpreted by the investigator at baseline (week -1) and week 56 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 56 were presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week -1, week 56
Reported as:
Count of participants · Participants
Change in Electrocardiogram (ECG)
ParticipantsLiraglutide 3.0 mgPlacebo
Normal (week -1)113133
Abnormal NCS (week -1)7860
Abnormal CS (week -1)44
Normal (week 56)118126
Abnormal NCS (week 56)6257
Abnormal CS (week 56)53
SecondaryChange in Laboratory Measurements (Haematology) - Haemoglobin

Change from baseline (week 0) to week 56 in haemoglobin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · mmol/L
Change in Laboratory Measurements (Haematology) - Haemoglobin
mmol/LLiraglutide 3.0 mgPlacebo
Change in Laboratory Measurements (Haematology) - Haemoglobin-0.1 ± 0.5-0.1 ± 0.6
SecondaryChange in Laboratory Measurements (Haematology) - Haematocrit

Change from baseline (week 0) to week 56 in Haematocrit was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Percentage of red blood cells
Change in Laboratory Measurements (Haematology) - Haematocrit
Percentage of red blood cellsLiraglutide 3.0 mgPlacebo
Change in Laboratory Measurements (Haematology) - Haematocrit-0.4 ± 2.8-0.2 ± 3.0
SecondaryChange in Laboratory Measurements (Haematology) - Erythrocytes

Change from baseline (week 0) to week 56 in erythrocytes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · 10^12 cells per liter (10^12 cells/L)
Change in Laboratory Measurements (Haematology) - Erythrocytes
10^12 cells per liter (10^12 cells/L)Liraglutide 3.0 mgPlacebo
Change in Laboratory Measurements (Haematology) - Erythrocytes-0.07 ± 0.27-0.04 ± 0.28
SecondaryChange in Laboratory Measurements (Haematology) - Thrombocytes, Leukocytes

Change from baseline (week 0) to week 56 in thrombocytes and leukocytes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · 10^9 cells/L
Change in Laboratory Measurements (Haematology) - Thrombocytes, Leukocytes
10^9 cells/LLiraglutide 3.0 mgPlacebo
Thrombocytes7 ± 457 ± 46
Leukocytes-0.22 ± 1.41-0.24 ± 1.28
SecondaryChange in Laboratory Parameters (Biochemistry) - Albumin

Change from baseline (week 0) to week 56 in albumin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Grams per deciliter (g/dL)
Change in Laboratory Parameters (Biochemistry) - Albumin
Grams per deciliter (g/dL)Liraglutide 3.0 mgPlacebo
Change in Laboratory Parameters (Biochemistry) - Albumin-0.1 ± 0.2-0.1 ± 0.2
SecondaryChange in Laboratory Parameters (Biochemistry) - Alkaline Phosphatase, Alanine Aminotransferase, Amylase, Aspartate Aminotransferase and Lipase

Change from baseline (week 0) to week 56 in alkaline phosphatase, alanine aminotransferase, amylase, aspartate aminotransferase and lipase was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Units per liter (U/L)
Change in Laboratory Parameters (Biochemistry) - Alkaline Phosphatase, Alanine Aminotransferase, Amylase, Aspartate Aminotransferase and Lipase
Units per liter (U/L)Liraglutide 3.0 mgPlacebo
Alkaline Phosphatase-1 ± 16-0 ± 15
Alanine Aminotransferase-5 ± 15-6 ± 18
Amylase13 ± 73-1 ± 22
Aspartate aminotransferase-3 ± 11-3 ± 14
Lipase30 ± 143-8 ± 47
SecondaryChange in Laboratory Parameters (Biochemistry) - Bicarbonate, Total Calcium, Potassium, Sodium and Urea

Change from baseline (week 0) to week 56 in bicarbonate, total calcium, potassium, sodium and urea was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · mmol/L
Change in Laboratory Parameters (Biochemistry) - Bicarbonate, Total Calcium, Potassium, Sodium and Urea
mmol/LLiraglutide 3.0 mgPlacebo
Bicarbonate serum0 ± 2-0 ± 2
Total Calcium-0.00 ± 0.11-0.02 ± 0.14
Potassium-0.0 ± 0.5-0.0 ± 0.5
Sodium-1 ± 2-0 ± 3
Urea0.1 ± 1.50.1 ± 1.4
SecondaryChange in Laboratory Parameters (Biochemistry) - Total Bilirubin and Creatinine

Change from baseline (week 0) to week 56 in total bilirubin and creatinine was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Micromoles per liter (umol/L)
Change in Laboratory Parameters (Biochemistry) - Total Bilirubin and Creatinine
Micromoles per liter (umol/L)Liraglutide 3.0 mgPlacebo
Total Bilirubin1.0 ± 3.90.6 ± 3.6
Creatinine-0.1 ± 8.7-0.2 ± 8.4
SecondaryChange in Laboratory Parameters (Biochemistry) - High Sensitive C-reactive Protein

Change from baseline (week 0) to week 56 in high sensitive C-reactive protein was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Milligrams per liter (mg/L)
Change in Laboratory Parameters (Biochemistry) - High Sensitive C-reactive Protein
Milligrams per liter (mg/L)Liraglutide 3.0 mgPlacebo
Change in Laboratory Parameters (Biochemistry) - High Sensitive C-reactive Protein-1.40 ± 8.02-1.29 ± 10.07
SecondaryChange in Laboratory Parameters (Biochemistry) - eGFR

Change from baseline (week 0) to week 56 in estimated GFR serum using Modification of Diet in Renal Disease (MDRD) formula was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Milliliters per minute per 1.73m^2
Change in Laboratory Parameters (Biochemistry) - eGFR
Milliliters per minute per 1.73m^2Liraglutide 3.0 mgPlacebo
Change in Laboratory Parameters (Biochemistry) - eGFR0 ± 131 ± 13
SecondaryChange in Laboratory Parameters (Biochemistry) - Uric Acid

Change from baseline (week 0) to week 56 in uric acid was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · mg/dL
Change in Laboratory Parameters (Biochemistry) - Uric Acid
mg/dLLiraglutide 3.0 mgPlacebo
Change in Laboratory Parameters (Biochemistry) - Uric Acid-0.2 ± 1.0-0.0 ± 0.9
SecondaryChange in Laboratory Parameters (Biochemistry) - Calcitonin

Change from baseline (week 0) to week 56 in calcitonin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Nanograms per liter (ng/L)
Change in Laboratory Parameters (Biochemistry) - Calcitonin
Nanograms per liter (ng/L)Liraglutide 3.0 mgPlacebo
Change in Laboratory Parameters (Biochemistry) - Calcitonin0.0 ± 1.50.0 ± 1.4
SecondaryChange in Laboratory Parameters (Biochemistry) - Thyroid Stimulating Hormone

Change from baseline (week 0) to week 56 in thyroid stimulating hormone was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.

Time frame:
Week 0, week 56
Reported as:
Mean · Milli-international units per liter
Change in Laboratory Parameters (Biochemistry) - Thyroid Stimulating Hormone
Milli-international units per literLiraglutide 3.0 mgPlacebo
Change in Laboratory Parameters (Biochemistry) - Thyroid Stimulating Hormone-0.0842 ± 1.22330.1002 ± 0.9493

Adverse events

Collected over From the date of first dose of trial product (week 0) to end of treatment (week 56) + post treatment follow-up of 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide 3.0 mg0/195 (0%)16/195 (8.2%)162/195 (83.1%)
Placebo0/197 (0%)19/197 (9.6%)141/197 (71.6%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventLiraglutide 3.0 mgPlacebo
OsteoarthritisMusculoskeletal and connective tissue disorders2/1950/197
Atrial flutterCardiac disorders0/1952/197
Adenocarcinoma pancreasNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1950/197
Amylase increasedInvestigations1/1950/197
Coronary artery diseaseCardiac disorders1/1950/197
DiverticulitisInfections and infestations1/1950/197
DiverticulumGastrointestinal disorders1/1950/197
Endometrial hyperplasiaReproductive system and breast disorders1/1950/197
Facial bones fractureInjury, poisoning and procedural complications1/1950/197
Intervertebral disc disorderMusculoskeletal and connective tissue disorders1/1950/197
Most frequent other events
Showing 10 of 24
Most frequent other events
EventLiraglutide 3.0 mgPlacebo
NauseaGastrointestinal disorders58/19523/197
DiarrhoeaGastrointestinal disorders45/19530/197
NasopharyngitisInfections and infestations42/19536/197
VomitingGastrointestinal disorders32/19512/197
HeadacheNervous system disorders29/19529/197
Upper respiratory tract infectionInfections and infestations24/19529/197
ConstipationGastrointestinal disorders28/19517/197
ArthralgiaMusculoskeletal and connective tissue disorders12/19524/197
InfluenzaInfections and infestations12/19522/197
Decreased appetiteMetabolism and nutrition disorders19/1955/197

Baseline characteristics

Age, Continuous
Age, Continuous(years)Liraglutide 3.0 mgPlaceboTotal
Mean55.9 ± 11.357.6 ± 10.456.8 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Liraglutide 3.0 mgPlaceboTotal
Female10899207
Male9099189
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Liraglutide 3.0 mgPlaceboTotal
Hispanic or Latino432972
Not Hispanic or Latino155169324
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Liraglutide 3.0 mgPlaceboTotal
American Indian or Alaska Native202
Asian358
Black or African American171128
Native Hawaiian or Other Pacific Islander202
White174180354
Other022
Body weight
Body weight(Kilograms (kg))Liraglutide 3.0 mgPlaceboTotal
Mean100.6 ± 20.898.9 ± 19.999.7 ± 20.3
09

Study locations

54 sites
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35294, United States
  • Novo Nordisk Investigational Site
    Concord, California 94520, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32205, United States
  • Novo Nordisk Investigational Site
    Plantation, Florida 33324, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Honolulu, Hawaii 96814, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Louisville, Kentucky 40213, United States
  • Novo Nordisk Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • Novo Nordisk Investigational Site
    Minneapolis, Minnesota 55416, United States
  • Novo Nordisk Investigational Site
    Butte, Montana 59701, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12206, United States
  • Novo Nordisk Investigational Site
    Wilmington, North Carolina 28401, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78731, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78749, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Winchester, Virginia 22601-3834, United States
  • Novo Nordisk Investigational Site
    Calgary, Alberta T2V 4J2, Canada
  • Novo Nordisk Investigational Site
    Edmonton, Alberta T6H 2L4, Canada
  • Novo Nordisk Investigational Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Novo Nordisk Investigational Site
    Hamilton, Ontario L8L 5G8, Canada
  • Novo Nordisk Investigational Site
    London, Ontario N6A 5B7, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M6G 1M2, Canada
  • Novo Nordisk Investigational Site
    Waterloo, Ontario N2J 1C4, Canada
  • Novo Nordisk Investigational Site
    Quebec, G1V 4G5, Canada
  • Novo Nordisk Investigational Site
    Dresden, 01307, Germany
  • Novo Nordisk Investigational Site
    Essen, 45219, Germany
  • Novo Nordisk Investigational Site
    Falkensee, 14612, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 22607, Germany
  • Novo Nordisk Investigational Site
    Leipzig, 04103, Germany
  • Novo Nordisk Investigational Site
    Münster, 48145, Germany
  • Novo Nordisk Investigational Site
    Rehlingen-Siersburg, 66780, Germany
  • Novo Nordisk Investigational Site
    Saint Ingbert-Oberwürzbach, 66386, Germany
  • Novo Nordisk Investigational Site
    Haifa, 35152, Israel
  • Novo Nordisk Investigational Site
    Jerusalem, 91120, Israel
  • Novo Nordisk Investigational Site
    Kfar Saba, 44281, Israel
  • Novo Nordisk Investigational Site
    Petah-Tikva, 49372, Israel
  • Novo Nordisk Investigational Site
    Tel Hashomer, 52621, Israel
  • Novo Nordisk Investigational Site
    Tel-Aviv, 64239, Israel
  • Novo Nordisk Investigational Site
    Bologna, 40138, Italy
  • Novo Nordisk Investigational Site
    Napoli, 80131, Italy
  • Novo Nordisk Investigational Site
    Palermo, 90127, Italy
  • Novo Nordisk Investigational Site
    Rome, 00168, Italy
  • Novo Nordisk Investigational Site
    Guadalajara, Jalisco 44600, Mexico
  • Novo Nordisk Investigational Site
    Monterrey, Nuevo León 64620, Mexico
  • Novo Nordisk Investigational Site
    Ankara, 06500, Turkey
  • Novo Nordisk Investigational Site
    Antalya, 07058, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34096, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34303, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34371, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34890, Turkey
  • Novo Nordisk Investigational Site
    Izmir, 35340, Turkey
10

References and documents

Publications

  • Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, Skovgaard D, Sugimoto D, Jensen C, Mosenzon O. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020 May;43(5):1085-1093. doi: 10.2337/dc19-1745. Epub 2020 Mar 5. PubMed 32139381 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Sep 2018, 19 months.

Results were first posted in Nov 2019, 1 year 2 months after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 19 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2016
First posted
Nov 15, 2016
StartActual
Feb 6, 2017
Primary completionActual
Sep 10, 2018
CompletionActual
Sep 25, 2018
Results first posted
Nov 27, 2019
Last update
Mar 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02963922
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 15, 2016
Start date
Feb 6, 2017
Primary completion
Sep 10, 2018
Completion
Sep 25, 2018
Results posted
Nov 27, 2019
Last update
Mar 30, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion